Prostate cancer — all decisions

The Board granted service connection for prostate cancer, finding a relationship between the Veteran's condition and his MOS as an Operating Room Specialist.

The Board remands the claim for service connection of prostate cancer to correct a pre-decisional duty to assist error and to attempt to obtain the Veteran's unit's Command Chronology.

The appeal of the proposed reduction in the service-connected prostate cancer rating from 100 percent to 20 percent was dismissed due to procedural issues.

The Board remands the claim for compensation under 38 U.S.C. § 1151 for prostate cancer due to an inadequate VA examination and missing private medical records.

The Board denied service connection for diabetes mellitus, type 2 and denied an initial compensable evaluation for prostate cancer residuals prior to April 3, 2023. However, the Board granted a 10 percent evaluation from April 3, 2023.

The Board denied the Veteran's request for an earlier effective date and a higher initial rating for prostate cancer, finding that the evidence did not support an earlier effective date or a higher rating.

The Board denied entitlement to special monthly compensation (SMC) based on statutory housebound criteria from June 25, 2019, to November 7, 2019.

The Board remands the claims for service connection for prostate cancer and type II diabetes mellitus to correct duty to assist errors related to the PACT Act.

The Board remands the service connection claim for residuals of prostate cancer due to a need for further development and consideration of evidence related to potential exposure to PD-680.

The Board denied service connection for rheumatoid arthritis and remanded the claims for diabetes mellitus, type II, sleep apnea, prostate cancer, urinary incontinence, residuals of gallbladder removal, gout, low back disability, and a TDIU prior to April 20, 2023.

The Board denied earlier effective dates for the grants of service connection for tinnitus and bilateral hearing loss, obstructive sleep apnea, prostate cancer, hypertension, bronchial asthma with chronic bronchitis, and CAD and atherosclerotic cardiovascular disease. However, an initial 10 percent disability rating was granted for hypertension.

The Board remands the claims for an initial compensable rating for prostate cancer, service connection for an eye disorder, a cardiovascular disorder, and obstructive sleep apnea due to inadequate VA examinations.

The Board granted service connection for the cause of the Veteran's death, which was determined to be pulmonary embolism due to prostate cancer, based on presumed exposure to herbicide agents during service in Vietnam.

The Board remands the claim for service connection for prostate cancer to the Agency of Original Jurisdiction (AOJ) for further development and issuance of a new supplemental statement of the case.

The Board denied service connection for chronic sinusitis and prostate cancer, finding that the weight of the evidence does not support a causal relationship between these conditions and in-service toxic exposure. The claims for service connection for right and left knee disabilities, spinal tumor, and parotid gland tumor were remanded due to deficiencies in prior VA examinations.

The Board granted an earlier effective date of September 26, 2019, for service connection for hypertension but denied the same for heart disability, DM, and prostate cancer.

The Board remands the claim for service connection for prostate cancer to obtain a VA examination and opinion, including an evaluation of toxic exposure risk activity (TERA) under the PACT Act.

The Board granted service connection for status post prostatectomy due to prostate cancer and erectile dysfunction, resolving all doubt in the Veteran's favor.

The Board denied service connection for prostate cancer as there is no evidence to support a finding that the Veteran's prostate cancer was incurred in or aggravated by his service, including exposure to herbicide agents or other chemical contaminants.

The Board granted service connection for hypertension and prostate cancer, both related to in-service herbicide agent exposure at Fort Chaffe.